Month: March 2023

SmartCentres Declares Distribution for March 2023

Written by Customer Service on March 16, 2023. Posted in Dividend Reports And Estimates.

TORONTO, March 16, 2023 (GLOBE NEWSWIRE) — SmartCentres Real Estate Investment Trust (“SmartCentres” or the “Trust”) (TSX:SRU.UN) announced today that the trustees of SmartCentres have declared a distribution for the month of March 2023 of CDN $0.15417 per trust unit, representing CDN $1.85 per unit on an annualized basis. Payment will be made on April 17, 2023 to unitholders of record on March 31, 2023. About SmartCentres SmartCentres Real Estate Investment Trust is one of Canada’s largest fully integrated REITs, with a best-in-class portfolio featuring 185 strategically located properties in communities across the country. SmartCentres has approximately $11.7 billion in assets and owns 34.8 million square feet of income producing value-oriented retail and first-class office space with 98.0% occupancy, on 3,500 acres of owned...

Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship

Written by Customer Service on March 16, 2023. Posted in Public Companies.

Provides $10 million upfront cash commitment to Lifecore for infrastructure preparation and production capacity preparation Customer to provide reimbursement for up to $15 million in capital expenditures to expand capacity Contemplates negotiation of multi-year amendment to extend and expand existing relationship CHASKA, Minn., March 16, 2023 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has entered into a term sheet (“Term Sheet”) to seek to expand its existing CDMO relationship with one of its long-term commercial Hyaluronic Acid and CDMO customers, including obtaining certain up-front cash payments and capital reimbursement obligations from the customer and entering into a non-binding agreement...

Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced financial results for the full year ended December 31, 2022, and provided an update on recent corporate developments. General Corporate Highlights Merger Agreement with DMK PharmaceuticalsIn October 2022, Adamis announced that it had initiated a process to explore a range of strategic and financing alternatives and had retained an investment bank to assist in evaluating certain alternatives focused on maximizing stockholder value. Potential alternatives to be considered...

Aerojet Rocketdyne Stockholders Approve Proposed Acquisition by L3Harris

Written by Customer Service on March 16, 2023. Posted in Mergers And Acquisitions.

EL SEGUNDO, Calif., March 16, 2023 (GLOBE NEWSWIRE) — Aerojet Rocketdyne Holdings, Inc. (NYSE: AJRD) (or the “Company”) announced that at a special meeting held today, its stockholders voted to approve the Company’s proposed acquisition by L3Harris Technologies (NYSE: LHX). 99.7% of votes cast were in favor of the transaction. “We are pleased with the strong support of our stockholders for this transaction with L3Harris,” said Eileen P. Drake, CEO and president of Aerojet Rocketdyne. “Today’s stockholder approval is another milestone in the process of bringing together our two world-class organizations to accelerate innovation and strengthen competition for national security and space exploration propulsion solutions. We remain focused on completing this transaction and delivering the significant expected benefits for our employees,...

Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

Company Announces Intention to Explore Strategic AlternativesSigns Term Sheet with Key Customer to Materially Expand Commercial RelationshipExpands Development Pipeline from 24 to 25 Active Projects as of Fiscal Second Quarter-endSubsequently Transitioned Three Projects to Commercialization with FDA Approval in Fiscal Third Quarter, Expanding Commercial Products from 26 to 29 with 14 CustomersFiscal Second Quarter Earnings Call Scheduled for March 17th, 2023 at 8:30 am Eastern Time CHASKA, Minn., March 16, 2023 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), reported results for the fiscal 2023 second quarter ended November 27, 2022. ANNOUNCEMENT OF INTENTION TO EXPLORE STRATEGIC ALTERNATIVES: Concurrently with the issuance...

Montauk Renewables Announces Full Year 2022 Results

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

PITTSBURGH, March 16, 2023 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company specializing in the management, recovery and conversion of biogas into renewable natural gas (“RNG”), today announced financial results for the year ended December 31, 2022. Full Year Highlights:Revenues of $205.6 million, increased 38.8% year-over-year Net Income of $35.2 million, increased 877.3% year-over-year Non-GAAP Adjusted EBITDA of $70.5 million, increased 152.4% year-over-year RNG production of 5.5 million MMBtu, decreased 2.9% year-over-yearMontauk’s full year revenue reflects an increase in pricing of both gas commodity and the average realized price of D3 Renewable Identification Numbers (“RINs”) sold. The increase in price offset a decrease in RNG volumes produced and the...

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2023 Financial Results

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

Southlake, Texas, March 16, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today provided a business update and reported financial results for the fiscal 2023 third quarter ended January 31, 2023. Key Milestones during Fiscal Q3 2023 and to date:Engaged in multi-year collaboration with Rutgers University to develop AI-based ECG algorithms Further international patents granted, bringing total patent portfolio to 40 (nine U.S., 31 internationally) Balance sheet strengthened through the amendment and exercise of pre-IPO bridge warrants, $15 million equity facility and extension...

SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024 Ongoing Phase 1 Study of CDK9 Inhibitor Suggests Broad Therapeutic Window and High Potential for Both Monotherapy and Combination Treatment $20 Million of Gross Proceeds from Capital Raise in February 2023 Adds to Cash Position of $17.1 Million as of December 31, 2022; Additional $13 Million Milestone Payment Expected in 1H 2023 NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the full year ended December 31, 2022 and provided a business update. “Broad success defines the past year, with positive efficacy signals...

Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2022. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. 2022 and early 2023 Highlights:Significant progress was made on the conduct of the ASPIRE global clinical trial studying ivospemin (SBP-101) in combination with gemcitabine and nab-paclitaxel in the first-line treatment of metastatic pancreatic ductal adenocarcinoma:Initiated ASPIRE trial in January 2022 Received approval from the Australian Human Research Ethics Committee (HREC) to expand the ASPIRE global clinical...

Locafy Reports Fiscal First Half 2023 Results

Written by Customer Service on March 16, 2023. Posted in Earnings Releases And Operating Results.

First Half 2023 Highlighted by 58% Total Revenue and 40% MRR Increases Year-Over-Year Product Upgrades and Cost Structure Optimization Drive Path to Profitability PERTH, Australia, March 16, 2023 (GLOBE NEWSWIRE) — Locafy Limited (Nasdaq: LCFY) (“Locafy” or the “Company”), a globally recognized software-as-a-service technology company specializing in local search engine marketing, today reported financial results for the 2023 fiscal first half ended December 31, 2022. Recent Operational HighlightsAnnounced an updated profitability timeline, highlighted by significant reductions in operational expenditures and the launch of Locafy Brand Boost and Keystone products. Locafy management now projects that the Company will reach profitability during the 2023 fiscal fourth quarter. Named as a finalist in the 2022-2023 Cloud Awards in...

Month: March 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals